Baxter International (NYSE:BAX) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Baxter International (NYSE:BAX) issued its earnings results on Thursday. The medical instruments supplier reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06, FiscalAI reports. The company had revenue of $2.98 billion during the quarter, compared to the consensus estimate of $2.91 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. Baxter International’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.69 earnings per share.

Here are the key takeaways from Baxter International’s conference call:

• Third-quarter results exceeded expectations: Sales rose 5% organically to approximately $3 billion, with broad-based growth led by Advanced Surgery, drug compounding, and infusion systems. Baxter raised its 2026 organic sales growth outlook to 3%-4% and lifted the low end of adjusted EPS guidance to $2.05-$2.15.
• Cash flow and deleveraging improved: Third-quarter free cash flow was $448 million, bringing year-to-date free cash flow to $705 million. Baxter also completed a $600 million tender offer that retired $854 million of debt and remains confident in reaching approximately 3x net leverage by year-end.
• Operational improvements continued across the portfolio, including better on-time shipments, improved quality metrics, cost savings, and more than 700 Baxter GPS continuous-improvement initiatives completed year to date. Advanced Surgery grew 12%, while HST margins expanded 140 basis points.
• Quality and portfolio actions create near-term pressure: Baxter will discontinue cephalosporin production at its Round Lake facility following supply and FDA warning-letter issues; the products are expected to contribute approximately $50 million in 2026 sales and $30 million in operating income. Management also flagged 2027 headwinds from product exits, the loss of tariff-refund benefits, inflation, tariffs, and the end of Vantive-related TSA services.

Baxter International Stock Down 7.8%

Shares of Baxter International stock traded down $1.98 during midday trading on Thursday, hitting $23.48. The company’s stock had a trading volume of 12,726,841 shares, compared to its average volume of 7,802,220. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $12.14 billion, a P/E ratio of -11.34, a PEG ratio of 3.83 and a beta of 0.65. The stock has a 50-day simple moving average of $24.72 and a 200-day simple moving average of $21.34.

Trending Headlines about Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Quarterly results exceeded expectations: Baxter reported adjusted earnings of $0.58 per share, above the $0.51–$0.52 consensus range, while revenue of $2.98 billion surpassed estimates of approximately $2.91 billion. Revenue increased 5% from the prior year. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Growth was broad-based: Segment-wide sales growth helped drive the quarterly beat, and management raised its 2026 financial outlook, providing a more constructive forward-looking signal for investors. Baxter Q3 Earnings Beat and 2026 Outlook Raised
• Positive Sentiment: Baxter also declared its regular quarterly dividend, supporting the stock’s income appeal. Baxter Raises Guidance and Declares Dividend
• Neutral Sentiment: The results indicate improving sales momentum, but investors will likely look for details on the revised 2026 outlook and whether growth can translate into stronger profitability.
• Negative Sentiment: Profitability remains a concern: Quarterly EPS declined from $0.69 a year earlier to $0.58, while Baxter continued to report a negative net margin. Analysts and investors may be discounting the earnings beat because cost and margin pressures remain unresolved. Baxter Reports Third-Quarter 2026 Results

Analyst Ratings Changes

Several research analysts have recently issued reports on BAX shares. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. TD Cowen upped their target price on Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. UBS Group increased their price target on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings cut Baxter International from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. Finally, Stifel Nicolaus lifted their price target on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Baxter International currently has a consensus rating of “Reduce” and an average price target of $21.73.

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.